Xencor (NASDAQ:XNCR) Stock Price Up 4.8%

Xencor, Inc. (NASDAQ:XNCR)’s share price shot up 4.8% during trading on Wednesday . The company traded as high as $20.85 and last traded at $20.77. 476,628 shares were traded during mid-day trading, a decline of 27% from the average session volume of 650,701 shares. The stock had previously closed at $19.81.

Analyst Ratings Changes

Several analysts have weighed in on XNCR shares. Royal Bank of Canada lowered their price objective on Xencor from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Friday, June 14th. Wedbush reiterated an “outperform” rating and set a $34.00 price target (down from $36.00) on shares of Xencor in a report on Thursday, June 13th. Raymond James dropped their price target on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. BMO Capital Markets decreased their price objective on shares of Xencor from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. Finally, BTIG Research dropped their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average price target of $35.38.

Xencor Trading Up 1.8 %

The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The firm has a market capitalization of $1.33 billion, a PE ratio of -9.80 and a beta of 0.69. The stock’s 50-day simple moving average is $20.87 and its 200-day simple moving average is $21.25.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The company had revenue of $12.80 million for the quarter, compared to the consensus estimate of $23.07 million. During the same period in the previous year, the firm posted ($1.02) EPS. The company’s revenue for the quarter was down 32.3% on a year-over-year basis. As a group, sell-side analysts expect that Xencor, Inc. will post -3.5 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In other news, VP John R. Desjarlais sold 36,329 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the transaction, the vice president now owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

Hedge funds have recently modified their holdings of the business. CWM LLC increased its stake in shares of Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,147 shares in the last quarter. Parallel Advisors LLC boosted its stake in Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,015 shares in the last quarter. Signaturefd LLC grew its holdings in Xencor by 367.7% in the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,151 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Xencor by 153.7% during the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,316 shares during the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of Xencor by 29,487.5% during the fourth quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,359 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.